← All Aurinia Pharmaceuticals INC filings

Aurinia Pharmaceuticals INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
AUPH
Aurinia Pharmaceuticals INC
10-K: Aurinia Pharmaceuticals Reports Strong 2025 Growth, LUPKYNIS Sales Up 25%
Aurinia Pharmaceuticals announced a significant increase in net product sales for LUPKYNIS and a substantial rise in net income for the fiscal year ended December 31, 2025.
NASDAQ
AUPH
Aurinia Pharmaceuticals INC
10-K: Aurinia Pharmaceuticals Reports Increased LUPKYNIS Sales and Strategic Restructuring in 2024
Aurinia Pharmaceuticals' 2024 10-K filing highlights a 36% increase in LUPKYNIS net product sales, strategic restructuring efforts, and ongoing development of AUR200.
NASDAQ
AUPH
Aurinia Pharmaceuticals INC
10-K/A: Aurinia Pharmaceuticals Files Amended 10-K, Details Strategic Shift and Financial Outlook
Aurinia Pharmaceuticals has filed an amendment to its 2023 annual report, including previously omitted information and updating its financial outlook, highlighting a strategic shift towards commercial execution and cost reduction.
NASDAQ
AUPH
Aurinia Pharmaceuticals INC
10-K: Aurinia Pharmaceuticals Concludes Strategic Review, Prioritizes LUPKYNIS Growth and Announces Share Repurchase Program
Aurinia Pharmaceuticals ends its strategic review, discontinues development of AUR200 and AUR300, and initiates a $150 million share repurchase program.